Dendritic cell immunotherapy induces antitumour response in parathyroid carcinoma and neuroendocrine pancreas carcinoma

Hormone and Metabolic Research

Volumn 31, Issue 12, 1999, Pages 662-664

  Schott, M ^a   Seissler, J ^a   Feldkamp, J ^a   Von Schilling, C ^a   Scherbaum, W A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Delayed Type Hypersensitivity; Dendritic Cell; Immunotherapy; Neuroendocrine Carcinoma; Pancreas; Parathyroid Carcinoma; Tumour Lysate

Indexed keywords

ADULT; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; CELL LYSATE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; FEMALE; HUMAN; IMMUNIZATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; MEMORY CELL; NEUROSECRETORY CELL; PANCREAS CARCINOMA; PARATHYROID CARCINOMA; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 0033393767     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978817     Document Type: Article

References (13)

1. 1 Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296
2. 2 Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 1997; 186: 665-672
3. 3 Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, Banchereau J. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180: 1841-1847
4. 4 Inaba K, Witmer PM, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994; 180: 1849-1860
5. 5 Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky JA. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol 1993; 5: 849-857
6. 6 Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332
7. 7 Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny KM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39-44
8. 8 Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93
9. 9 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118
10. 10 Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196 (2): 137-152
11. 11 Schott M, Feldkamp J, Schattenberg D, Seissler J, Scherbaum WA. Dendritic cell immunotherapy in disseminated parathyroid carcinoma. Lancet 1999; 353: 1188-1189
12. 12 Shane E, Bilezikian JP. Parathyroid carcinoma: a review of 62 patients. Endocr Rev 1982; 3: 218-226
13. 13 Bukowski RM, Sheeler L, Cunningham J, Esselstyn C. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med 1984; 144: 399-400